仑伐替尼、特瑞普利单抗联合肝动脉灌注化疗治疗高危晚期肝细胞癌:生物分子探索性II期试验
这项单中心、单臂II期试验纳入36例高危晚期肝细胞癌患者,接受仑伐替尼、特瑞普利单抗联合FOLFOX-HAIC一线治疗。6个月无进展生存率为80.6%,中位无进展生存期10.4个月,客观缓解率63.9%。CCL28和BTC低水平患者预后不佳。
要点
- 联合方案6个月无进展生存率达80.6%,中位无进展生存期10.4个月。
- 客观缓解率63.9%,中位缓解持续时间14.4个月,未报告治疗相关死亡。
- CCL28和BTC低水平可能提示预后不佳,或为预测生物标志物。
核心结论
- 仑伐替尼、特瑞普利单抗联合FOLFOX-HAIC对高危晚期肝细胞癌显示出安全且令人鼓舞的抗肿瘤活性。
- CCL28和BTC水平可能是该三联治疗的预测生物标志物。
研究设计与样本
- II期、单中心、单臂试验。
- 筛查51例,36例高危晚期肝细胞癌患者接受仑伐替尼、特瑞普利单抗联合FOLFOX-HAIC治疗。
- 治疗方案为21天一个周期。
- 主要终点为按RECIST评估的6个月无进展生存率。
主要发现
- 36例参与者中86.1%具有高危特征。
- 6个月无进展生存率为80.6%(95% CI,64.0%-91.8%),达到主要终点。
- 中位无进展生存期为10.4个月(95% CI,5.8-15.0)。
- 预设最终分析时中位总生存期未达到,延长随访后为17.9个月(95% CI,14.5-21.3)。
- 按RECIST的客观缓解率为63.9%,按mRECIST为66.7%;中位缓解持续时间为14.4个月(95% CI,8.9-19.9)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The combination of lenvatinib, toripalimab and hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) suggested encouraging antitumour activity in our retrospective study. We hereby prospectively establish the efficacy, safety and predictive biomarkers of the combination therapy as a first-line treatment in patients with high-risk advanced hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This phase II, single-centre, single-arm trial enrolled advanced HCC participants with high-risk. Of 51 screened participants, 36 received lenvatinib, toripalimab plus FOLFOX-HAIC. Participants received 21-day treatment cycles of lenvatinib, toripalimab, and FOLFOX-HAIC. The primary end-point was the progression-free survival (PFS) rate per RECIST at six months. RESULTS: Thirty-six participants (86.1% with high-risk features) were enrolled in our study. The primary end-point was met with a PFS rate of 80.6% (95% CI, 64.0%-91.8%) at six months. The median PFS was 10.4 months (95% CI, 5.8-15.0), and the median OS was not reached at the prespecified final analysis and was 17.9 months (95% CI, 14.5-21.3) after follow-up was extended. The ORR per RECIST was 63.9%, and per mRECIST was 66.7%. The median duration of response was 14.4 months (95% CI, 8.9-19.9). The most common adverse events were thrombocytopenia, elevated aspartate aminotransferase, and hypertension, and no treatment-related death was reported. Participants with low levels of both CCL28 and BTC had unsatisfactory prognosis. CONCLUSIONS: Lenvatinib, toripalimab and FOLFOX-HAIC showed safe and encouraging antitumour activity for advanced HCC with high-risk features. The levels of CCL28 and BTC might be the predictive biomarkers for the triple combination therapy.
引用
- Lai Z, He M, Bu X, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. Eur J Cancer. 2022. PMID: 35981413. doi:10.1016/j.ejca.2022.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。